Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nu-lotan Reduces Casual BP in 3 Months: Interim Analysis of J-HEALTH
April 25, 2005
- US Requests 80% of Clin. Trial Consultations Within 60 Days of Application
April 25, 2005
- 991 Facilities Registered with JMA's Clin. Trial Network
April 25, 2005
- REGULATORY NEWS IN BRIEF
April 25, 2005
- R&D NEWS IN BRIEF
April 25, 2005
- The Reporter's Eye: 7
April 25, 2005
- NEW PRODUCTS
April 25, 2005
- Univ. Students Rank 4 Pharma Companies Among Top 100 Choices
April 25, 2005
- Precious-i: MEDIC INFO
April 25, 2005
- SEMINAR
April 25, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 25, 2005
- JMA Opposed to Medical License Renewal: Dr Uematsu
April 25, 2005
- Bayer Yakuhin Aims for Sales of \100 Bil. by 2010
April 25, 2005
- Working Group
April 25, 2005
- CROs Should Be General "Pharma Support Providers": Mr Nakamura
April 25, 2005
- The Reporter's Eye: 8
April 25, 2005
- Nichi-iko to Assign Expert MRs to DPC Hospitals
April 25, 2005
- JIRA Presents Data on Economic Benefits of Image Diagnosis
April 25, 2005
- Employees Not Necessarily Accepting Pay for Performance
April 18, 2005
- REGULATORY NEWS IN BRIEF
April 18, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…